The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Linda Fabris; Yvonne Ceder; Arul M Chinnaiyan; Guido W Jenster; Karina D Sorensen; Scott Tomlins; Tapio Visakorpi; George A Calin

doi:10.1016/j.eururo.2015.12.054

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Linda Fabris, Yvonne Ceder, Arul M Chinnaiyan, Guido W Jenster, Karina D Sorensen, Scott Tomlins, Tapio Visakorpi, George A Calin

Research output: Contribution to journal › Review article › peer-review

Abstract

Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management.

Original language	English
Pages (from-to)	312-322
Journal	European Urology
Volume	70
Issue number	2
Early online date	2016 Jan 21
DOIs	https://doi.org/10.1016/j.eururo.2015.12.054
Publication status	Published - 2016

Subject classification (UKÄ)

Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2015.12.054

http://www.ncbi.nlm.nih.gov/pubmed/26806656?dopt=Abstract

Cite this

@article{3db993e8c6234e9cac6dc2dd75718d30,

title = "The Potential of MicroRNAs as Prostate Cancer Biomarkers.",

abstract = "Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management.",

author = "Linda Fabris and Yvonne Ceder and Chinnaiyan, {Arul M} and Jenster, {Guido W} and Sorensen, {Karina D} and Scott Tomlins and Tapio Visakorpi and Calin, {George A}",

year = "2016",

doi = "10.1016/j.eururo.2015.12.054",

language = "English",

volume = "70",

pages = "312--322",

journal = "European Urology",

issn = "1873-7560",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - The Potential of MicroRNAs as Prostate Cancer Biomarkers.

AU - Fabris, Linda

AU - Ceder, Yvonne

AU - Chinnaiyan, Arul M

AU - Jenster, Guido W

AU - Sorensen, Karina D

AU - Tomlins, Scott

AU - Visakorpi, Tapio

AU - Calin, George A

PY - 2016

Y1 - 2016

N2 - Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management.

AB - Short noncoding RNAs known as microRNAs (miRNAs) control protein expression through the degradation of RNA or the inhibition of protein translation. The miRNAs influence a wide range of biologic processes and are often deregulated in cancer. This family of small RNAs constitutes potentially valuable markers for the diagnosis, prognosis, and therapeutic choices in prostate cancer (PCa) patients, as well as potential drugs (miRNA mimics) or drug targets (anti-miRNAs) in PCa management.

U2 - 10.1016/j.eururo.2015.12.054

DO - 10.1016/j.eururo.2015.12.054

M3 - Review article

C2 - 26806656

SN - 1873-7560

VL - 70

SP - 312

EP - 322

JO - European Urology

JF - European Urology

IS - 2

ER -

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this